Finally, a large subsequent trial comparing equivalent doses of S/V to ACE inhibitors or angiotensin receptor blockers (ARBs) showed no differences in mortality or heart failure hospitalization after myocardial infarction [6], a finding confirmed by a recent meta-analysis [16]. This evidence concerns the gene ACE and heart failure.